Brian Brown,Hui-Ju Chen,David DeGoey,Geoff Halvorsen,John Hartung,Howard R. Heyman,Nathan Ide,Dale Kempf,Allen C. Krueger,Tao Li,Tongmei Li,Steven R. Martinez,Christopher C. Marvin,John T. Randolph,Er
申请号：
US16461823
公开号：
US20190358214A1
申请日:
2017.11.13
申请国别(地区):
US
年份:
2019
代理人:
摘要：
The present invention features compositions and methods for the treatment of HCV infection. In one embodiment, the compositions of the invention comprise (1) Compound 1 or a pharmaceutically acceptable salt thereof, and (2) Compound 2a or a pharmaceutically acceptable salt thereof. In another embodiment, the compositions of the invention comprise (1) Compound 1 or a pharmaceutically acceptable salt thereof, and (2) a prodrug of Compound 2a (e.g., one of Compounds 2b-2k or Examples 3-1 to 3-10) or a pharmaceutically acceptable salt of said prodrug.
